Walleye Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History

Walleye Trading’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.45M	Buy	61,100 +4,700	+8%	+$274K	0.01%	1369
2025 Q4	$3.35M	Buy	56,400 +24,700	+78%	+$1.34M	﹤0.01%	1542
2025 Q3	$1.72M	Sell	31,700 -8,600	-21%	-$492K	﹤0.01%	1914
2025 Q2	$2.22M	Sell	40,300 -3,300	-8%	-$194K	﹤0.01%	1668
2025 Q1	$3.08M	Buy	43,600 +32,700	+300%	+$2.2M	0.01%	1372
2024 Q4	$716K	Buy	10,900 +4,900	+82%	+$328K	﹤0.01%	2376
2024 Q3	$422K	Buy	6,000 +3,600	+150%	+$301K	﹤0.01%	2621
2024 Q2	$198K	Sell	2,400 -12,800	-84%	-$1.07M	﹤0.01%	3097
2024 Q1	$1.33M	Sell	15,200 -3,400	-18%	-$304K	﹤0.01%	2015
2023 Q4	$1.79M	Buy	18,600 +12,700	+215%	+$1.12M	﹤0.01%	2012
2023 Q3	$522K	Sell	5,900 -75,900	-93%	-$6.75M	﹤0.01%	2929
2023 Q2	$7.09M	Sell	81,800 -23,200	-22%	-$2.18M	0.02%	742
2023 Q1	$10.2M	Buy	105,000 +31,600	+43%	+$3.28M	0.02%	620
2022 Q4	$7.6M	Buy	73,400 +41,400	+129%	+$3.89M	0.02%	819
2022 Q3	$2.71M	Sell	32,000 -11,300	-26%	-$1.01M	0.01%	1474
2022 Q2	$3.59M	Buy	43,300 +31,000	+252%	+$2.47M	0.01%	1232
2022 Q1	$948K	Buy	12,300 +8,900	+262%	+$745K	﹤0.01%	2275
2021 Q4	$300K	Sell	3,400 -4,000	-54%	-$330K	﹤0.01%	3477
2021 Q3	$572K	Buy	+7,400	New	+$584K	﹤0.01%	2778
2021 Q2	–	Sell	-3,100	Closed	-$234K	–	5159
2021 Q1	$234K	Sell	3,100 -400	-11%	-$32.7K	﹤0.01%	3478
2020 Q4	$307K	Buy	3,500 +700	+25%	+$55.5K	﹤0.01%	3115
2020 Q3	$213K	Sell	2,800 -4,500	-62%	-$455K	﹤0.01%	2945
2020 Q2	$900K	Buy	7,300 +300	+4%	+$29.8K	0.01%	1753
2020 Q1	$592K	Buy	7,000 +6,300	+900%	+$543K	﹤0.01%	1736
2019 Q4	$59K	Sell	700 -24,100	-97%	-$1.82M	﹤0.01%	3755
2019 Q3	$1.67M	Buy	24,800 +16,500	+199%	+$1.27M	0.01%	1199
2019 Q2	$711K	Sell	8,300 -28,200	-77%	-$2.41M	0.01%	1892
2019 Q1	$3.24M	Buy	36,500 +30,000	+462%	+$2.78M	0.03%	747
2018 Q4	$553K	Buy	6,500 +2,500	+63%	+$238K	﹤0.01%	2380
2018 Q3	$388K	Buy	+4,000	New	+$399K	﹤0.01%	3154
2018 Q2	–	Sell	-6,200	Closed	-$503K	–	4555
2018 Q1	$503K	Buy	+6,200	New	+$532K	﹤0.01%	2649
2017 Q4	–	Sell	-1,000	Closed	-$93	–	4347
2017 Q3	$93	Hold	1,000	–	–	﹤0.01%	3634
2017 Q2	$91	Buy	1,000 +900	+900%	+$81.9K	﹤0.01%	3596
2017 Q1	$9	Sell	100 -100	-50%	-$8.9K	﹤0.01%	4351
2016 Q4	$16K	Hold	200	–	–	﹤0.01%	4162
2016 Q3	$18K	Sell	200 -1,100	-85%	-$104K	﹤0.01%	4219
2016 Q2	$101K	Sell	1,300 -800	-38%	-$68K	﹤0.01%	3501
2016 Q1	$172K	Buy	+2,100	New	+$171K	﹤0.01%	2906
2015 Q4	–	Sell	-500	Closed	-$53K	–	5281
2015 Q3	$53K	Sell	500 -13,600	-96%	-$1.82M	﹤0.01%	3459
2015 Q2	$1.93M	Buy	+14,100	New	+$1.75M	0.02%	721

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Trading's BMRN Position: Q4 2025 in Review

Walleye Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,407 shares — an estimated $240K sold.

Walleye Trading first reported a position in BMRN in Q2 2015 and held it in 37 quarters. The position peaked at $7.69M in Q2 2024. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Walleye Trading reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Walleye Trading sold 4,407 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $240K.
Walleye Trading first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 37 quarters.
Walleye Trading's BioMarin Pharmaceuticals position peaked at $7.69M in Q2 2024.
538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Walleye Trading's 13F filing for Q4 2025, filed 13 Feb 2026.